EFFICACY AND SAFETY OF RIFAXIMIN FOR PATIENTS WITH CHRONIC INTESTINAL PSEUDO-OBSTRUCTION: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A TRIAL

Takaomi Kessoku  ¹     Hidenori Ohkubo  ¹     TOMOKI OGATA  ¹     Tsumugi Jono  ¹     Kosuke Tanaka  ¹     Kota Takahashi  ¹     Atsushi Yamamoto  ¹     Tomohiro Takatsu  ¹     Tsutomu Yoshihara  ¹     Noboru Misawa  ¹     Keiichi Ashikari  ¹     Akiko Fuyuki  ¹     Takuma Higurashi  ¹     Toshihiro Misumi  ²     Satoru Shinoda  ²     Yukako Horikoshi  ³     Emi Misugi  ³     Hiroe Asuke  ⁴     Katsuhiko Miyazawa  ⁴     Ikuya Sato  ⁴     Atsushi Nakajima  ^1    
1 Yokohama City University Graduate School of Medicine, Yokohama, Japan
² Yokohama City University School of Medicine, Yokohama, Japan
³ Yokohama City University Hospital, Yokohama, Japan
⁴ ASKA Pharmaceutical Co., Ltd., Tokyo, Japan

Session
Small intestinal (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)